Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.41 |
| ▸ | CTSL | P07711 | 8/20 | 0.41 |
| ▸ | CTSB | P07858 | 6/20 | 0.41 |
| ▸ | CTSS | P25774 | 6/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2157035 | 0.92 | CTSK (0.47) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2156321 | 0.92 | CTSK (0.47) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2155864 | 0.92 | CTSK (0.47) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2155876 | 0.89 | CTSK (0.44) | CTSKCTSLCTSBCTSS | |
| SCHEMBL2157216 | 0.88 | CTSK (0.42) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2155792 | 0.86 | CTSK (0.38) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2157201 | 0.86 | CTSK (0.38) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2156245 | 0.86 | CTSK (0.38) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2155648 | 0.84 | CTSK (0.36) | CTSKCTSLCTSBCTSSALOX5 | |
| SCHEMBL2156565 | 0.84 | CTSK (0.48) | CTSKCTSLCTSBCTSSALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | claimed |
| US-7973037-B2 | Cathepsin cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | claimed |
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-7973037-B2 | Cathepsin cysteine protease inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2011-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230446-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTSZ | CTSK 4/4885CTSL 8/4885CTSB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.